Trial Profile

A Phase II/III Study Comparing HX008 (a Humanized Monoclonal Antibody Against PD-1) Plus Chemotherapy With Pembrolizumab Plus Chemotherapy as the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Pucotenlimab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Taizhou Hanzhong Pharmaceuticals

24 Oct 2023 Results (n=43; From September 25th, 2020 to April 15th, 2021) assessing the efficacy and safety of pucotenlimab for nsq-NSCLC without EGFR/ALK mutations, presented at the 48th European Society for Medical Oncology Congress.
12 Feb 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com